Matt Miksic from Barclays lowered the price target on Becton, Dickinson, and Company (NYSE:BDX) from $261 to $241, while ...

Enrollment in a patient-delivered intervention allowed adults with overweight or obesity to better maintain weight loss than ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...